Prefusion HPIV F Immunogens and Their Use. | Office of Technology Transfer, NIH

Prefusion HPIV F Immunogens and Their Use. | Office of Technology Transfer, NIH

Licensing Opportunity:

Stabilized Prefusion F Immunogens for the Prevention of Human Parainfluenza Virus (HPIV)

Transmission electron microscopic (TEM) image revealed some of the nucleocapsid morphology displayed by the human parainfluenza virus type-4a (HPIV-4), a member of the Paramyxoviridae family. Credit: CDC

Human parainfluenza virus (HPIV) is an RNA-based paramyxovirus that causes respiratory infections in children and adults. There are four serotypes that can result in myriad diseases of the respiratory tract including croup, bronchitis, and pneumonia. Currently, there are limited treatment options and no approved vaccines.



NIAID researchers have created immunogenic HPIV fusion (F) glycoproteins for types 1,2,3, and 4 (HPIV1, HPIV2, HPIV3, and HPIV4) that have been modified to stabilize the prefusion conformation. These stabilized prefusion F immunogens, especially HPIV3, induced high titer neutralizing responses in mice and rhesus macaques and may serve as promising candidates for the prevention of HPIV infection. Read more about this exciting collaboration opportunity: https://www.ott.nih.gov/technology/e-215-2016-0